Pan-cancer profiling of FZD2 as a prognostic biomarker: integrative multi-omics analysis with experimental validation and functional characterization in gastric cancer

Sijiang Zhou, Da Li, Chao Quan, Yu Zhu, Yue Feng, Shengyu Wang, Yongle Li, Tongtong Qi, Junqiang ChenFrontiers in Pharmacology 2025 · DOI

Abstract

Frizzled class receptor 2 (FZD2) is widely upregulated in various tumor types, with its expression closely associated with key clinical outcomes, including overall survival, disease-specific survival, disease-free interval, as well as tumor mutations, drug sensitivity, immune cell infiltration, and immunotherapy-related biomarkers such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI). These findings highlight the pivotal role of FZD2 in cancer prognosis and treatment, offering potential for novel therapeutic approaches and the development of personalized medicine strategies in oncology.

Introduction

Precision oncology relies on the identification of robust molecular signatures that can predict disease progression and therapeutic response. While the Wnt signaling pathway has long been implicated in oncogenesis, the specific role of Frizzled class receptor 2 (FZD2) across diverse cancer types has remained largely uncharacterized. This study provides a comprehensive pan-cancer analysis of FZD2, mapping its expression landscape, prognostic significance, and impact on the tumor microenvironment.

Methodology: An Integrated Pipeline

The researchers utilized a robust "dry lab to wet lab" workflow to bridge the gap between computational predictions and biological reality.

Figure 1: The integrated research workflow combining pan-cancer bioinformatic screening with experimental validation in gastric cancer models.

Bioinformatic Screening

The study mined large-scale datasets from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) project to evaluate FZD2 expression across 33 cancer types. Advanced algorithms, including CIBERSORT and ESTIMATE, were employed to map immune cell infiltration, while the pRRophetic R package predicted drug sensitivity based on gene expression profiles.

Experimental Validation

Focusing on Gastric Cancer (STAD) as a primary model, the team performed functional assays using siRNA to silence FZD2 in AGS and HGC-27 cell lines. These "wet lab" experiments included CCK-8 proliferation assays, Transwell migration tests, and wound-healing assays. Finally, in vivo xenograft models in nude mice were established to observe the effects of FZD2 silencing on tumor growth in a living organism.

Pan-Cancer Expression and Prognostic Value

FZD2 was found to be significantly overexpressed in a wide array of malignancies compared to normal tissues. Notable upregulation was observed in stomach adenocarcinoma (STAD), bladder urothelial carcinoma (BLCA), and cholangiocarcinoma (CHOL).

Figure 2: Pan-cancer expression levels of FZD2 across 33 tumor types (red) compared to normal tissues (blue), showing significant upregulation in the majority of cancers.

Beyond mere diagnosis, FZD2 serves as a critical prognostic indicator. High expression levels consistently correlated with shorter Overall Survival (OS) and Disease-Free Survival (DFS), particularly in kidney renal clear cell carcinoma (KIRC), lower-grade glioma (LGG), and gastric cancer. Receiver Operating Characteristic (ROC) analysis further confirmed its diagnostic power, yielding an Area Under the Curve (AUC) of 0.858 for gastric cancer.

Immune Microenvironment and Genomic Instability

A key finding of the study is the relationship between FZD2 and the tumor microenvironment. High FZD2 expression strongly correlated with the infiltration of M2 macrophages—cells known to suppress the immune response—and markers of T-cell exhaustion. This suggests that FZD2 may help tumors construct an "immune shield" to evade natural defenses.

Furthermore, FZD2 expression was linked to genomic instability markers like TMB and MSI. This correlation suggests that FZD2 levels could serve as a proxy for identifying patients who might be more responsive to immune checkpoint inhibitors.

Functional Characterization in Gastric Cancer

Experimental results validated the bioinformatic predictions. In vitro, knocking down FZD2 in gastric cancer cells reduced migration and invasion by approximately 50% and significantly increased apoptosis (programmed cell death). In the in vivo mouse models, tumors with silenced FZD2 were substantially smaller in both volume and weight compared to control groups (p < 0.01), demonstrating that FZD2 is a viable therapeutic target.

Conclusion

FZD2 emerges as a versatile "Swiss Army Knife" biomarker in oncology. Its consistent upregulation across cancers, coupled with its influence on immune evasion and drug sensitivity, positions it as a high-priority target for future drug development. While further clinical trials are necessary to translate these findings to the bedside, FZD2 represents a significant step forward in the quest for personalized cancer treatment.

Summary updated

Abstract

FZD2 is widely upregulated in various tumor types, with its expression closely associated with key clinical outcomes, including overall survival, disease-specific survival, disease-free interval, as well as tumor mutations, drug sensitivity, immune cell infiltration, and immunotherapy-related biomarkers such as TMB and MSI. These findings highlight the pivotal role of FZD2 in cancer prognosis and treatment, offering potential for novel therapeutic approaches and the development of personalized medicine strategies in oncology.
BibTeX
@inproceedings{zhou2025pan,
  author = {Sijiang Zhou and Da Li and Chao Quan and Yu Zhu and Yue Feng and Shengyu Wang and Yongle Li and Tongtong Qi and Junqiang Chen},
  title = {{Pan-cancer profiling of FZD2 as a prognostic biomarker: integrative multi-omics analysis with experimental validation and functional characterization in gastric cancer}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2025.1534974},
}
Figure